Melanotan I

Melanotan I Reproductive & Neurological Pathway

Melanotan I stands as a pinnacle compound within the regulation of highly specific behavioral and reproductive neurological networks, driving intense, localized receptor cascades.

Pharmacological Metrics

Parameter	Value
Molecular Formula	C78H111N21O19
Molecular Mass	1646.9 g/mol
Assay Purity	>98.5%
Appearance	White-to-off-white powder

Figure 1: Conceptual Action of Melanotan I

Neurological Transduction Pattern

Detailed cascade of actions governing its physiological mapping:

1. Functions exactly as a targeted, linear analogue of α-MSH.
2. Binds almost exclusively to the Melanocortin-1 Receptor (MC1R).
3. Severely limits the cross-activation of MC4R seen heavily in Melanotan II.
4. Upregulates eumelanin production directly within the skin's melanocytes.
5. Provides massive protection against UV-induced oxidative DNA damage (erythema).

Figure 2: Rate of Systemic Neuro-Activation

Primary Research Results

• Outcome 1: Used clinically to prevent severe photosensitivity disorders (Erythropoietic Protoporphyria).
• Outcome 2: Grants deep, protective melanogenesis without the nausea and hyper-libido side effects.
• Outcome 3: Provides a vastly safer, completely linear research profile compared to MT2.

Selective MC1R Agonism & Photoprotection

Melanotan I (afamelanotide, [Nle&sup4;, D-Phe&sup7;]-α-MSH) is a linear 13-amino acid analogue of α-MSH engineered for enhanced potency and selectivity at the melanocortin-1 receptor (MC1R). Unlike Melanotan II, its linear structure and amino acid substitutions produce a significantly narrower receptor profile: strong MC1R agonism with minimal activity at MC3R, MC4R, and MC5R. This selectivity means Melanotan I produces UV-independent tanning and photoprotection without the appetite-suppressive and pro-sexual effects associated with broader melanocortin activation.

1. Afamelanotide binds MC1R on epidermal melanocytes with approximately 100-fold greater affinity than native α-MSH.
2. MC1R activation stimulates adenylyl cyclase → cAMP → PKA → MITF transcription, upregulating the entire melanogenic enzyme cascade (tyrosinase, TYRP1, TYRP2).
3. Eumelanin (brown-black, photoprotective) production is specifically enhanced over pheomelanin (red-yellow, phototoxic), shifting the melanin ratio favorably.
4. The resulting eumelanin deposition provides DNA-protective UV absorption and free radical scavenging in the suprabasal epidermis.
5. A single subcutaneous implant (16 mg slow-release) produces sustained melanogenesis for approximately 60 days in clinical studies.

Approved Medical Use & Research

• Scenesse® Approval: Afamelanotide is approved by the EMA (2014) and FDA (2019) as Scenesse® for erythropoietic protoporphyria (EPP), a rare genetic disorder causing extreme photosensitivity.
• EPP Mechanism: EPP patients accumulate protoporphyrin IX in skin, causing severe pain upon light exposure. Afamelanotide-induced eumelanin provides a physical UV shield, increasing pain-free light exposure time by 70–80%.
• Vitiligo Research: Combination therapy with narrowband UVB and afamelanotide accelerates repigmentation in vitiligo patients compared to NB-UVB alone, by enhancing melanocyte proliferation and migration.
• Skin Cancer Prevention: Phase 2 studies in organ transplant recipients (who have 100x increased SCC risk) are investigating whether eumelanin induction reduces actinic keratosis and SCC incidence.
• Distinction: MT-I carries the significant advantage of regulatory approval and a well-characterized safety profile from multi-year clinical trials, unlike the research-only status of MT-II.